1 / 7

Indinavir/Ritonavir 800/200 mg bid based regimen in multi-experienced HIV positive patients with

Indinavir/Ritonavir 800/200 mg bid based regimen in multi-experienced HIV positive patients with extensive drug resistance. A.Vincenti1, L. Vatteroni2, F.Pacini1, A.Scasso1. 1)Hospital Lucca 2) University Pisa, Italy.

lila-hendrix
Download Presentation

Indinavir/Ritonavir 800/200 mg bid based regimen in multi-experienced HIV positive patients with

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Indinavir/Ritonavir 800/200 mg bid based regimen in multi-experienced HIV positive patients with extensive drug resistance. A.Vincenti1, L. Vatteroni2, F.Pacini1, A.Scasso1. 1)Hospital Lucca 2) University Pisa, Italy

  2. An efficacious salvage regimen for multi-experienced patients failing PI has not been yet established

  3. We evaluated a IDV/RTV 800/200mg b.i.d. regimen in combination with 2 NRTI with at least one of these efficacious toward the virus, in patients with virological multiple failure on a PI based regimen including IDV.

  4. We enrolled 6 patients, that have been heavily pretreated and prior to initiating therapy, genotyping testing was performed revealing resistance both IDV and RTV. All patients were men, average age 46 yrs, (range 35-70). One patient had a vRNA very hight (6.8x106 cop/ml), CD4+30 cells/mmc; in the other 5 patients the median vRNA was 5.2log cop/ml, the median CD4+208 cells/mmc.

  5. CD4+ c/mmc 0 w 12ws 48ws 1°pt 30 100 126 2°pt 105 *126 145 3°pt 121 245 294 4°pt 133 167 219 5°pt 470 788 6°pt 211 258 *the patient underwent a corneal transplantation for a cheratoconus with good results.

  6. vRNA c/ml 0 w 12ws 48ws 1°pt 6.8x106 7.4x104 1.9x104 2°pt 3.9x105 *1.6x104 1.7x103 3°pt 2.5x105 <102 4°pt 1.3x104 <102 <102 5°pt 7.1x 104 1.5x102 6°pt 6.9x104 3.9x103 *the patient underwent a corneal transplantation for a cheratoconus with good results.

  7. CONCLUSIONS *These data show that an enhanced PI regimen of IDV/RTV 800/200mg b.i.d. in combination with 2 NRTI was successfull in overcoming virological failure in heavily pretreated patients. *This regimen has a role as a salvage therapy also in patients that are resistant to these PI. *The regimen was well tolerated; no patient had clinical adverse events or nephrolitiasis.

More Related